PubMed Health⌕ Search

Biomedical subjects

J Armata

Publications and source records attributed to J Armata.

At least 55 records · Page 3Linked to original sources
PubMed1993

Relapses after termination of therapy of acute lymphoblastic leukemia in children.

In the past 16 years, 2004 children with acute lymphoblastic leukemia (ALL) have been treated in the Polish Pediatric Group centers. Eight hundred and eighty-seven (44.3%) of these patients discontinued treatment after the first remission. Acute lymphoblastic leukemia relapse occurred in 180 patients (20.3%). This group was analyzed for the method of treatment and its influence on long-term survival, the time between cessation of treatment and relapse, the character and localization of relapse and later follow-up. It was shown that the patients with the best chance of a second remission are those with late testicular relapse. The most frequent and prognostically poor are bone marrow (BM) relapses which warrant intensive chemotherapy with BM transplantation. Patients with ALL relapse still have the possibility of a second remission and long-term survival.

Adolescent↗
PubMed1993

[Results of treating chronic myelogenous leukemia in children].

Retrospective analysis of the results of treatment chronic myeloid (CML) leukemia in 80 children was done. From among 72 children treated by conventional methods the probability of 10 years survival had 17%. Statistically significant better results was obtained in the group of children with adult than juvenile type of CML (23 and 8%). Allogenic bone marrow transplantation was performed in six children, two children were treated with interferon. New approaches of treatment may offer the better chance for constitution of normal bone marrow function.

Adolescent↗
PubMed1993

[Acute lymphoblastic leukemia in infants--results of treatment according to infant leukemia protocol--POG 8493].

Analysis was made of ALL treatment results according program POG 8493 in 9 infants. In 4 children WBC exceeded 100.0 G/l, and in 5 children CNS was affected. Eight infants had remission, six had relapse (mainly BM): early up to 8 month in 5, late--in 52 month in one girl. Four children died after relapse, four are still living: 2 I RC (2 and 23 months), 2 in II RC (1 month and 23 month). Probability of 4-year EFS was 0.25 and that survival--0.44. In view of continuing poor ALL prognosis, in infants it is necessary to look for more effective methods of treatment.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1992

[Late complications in patients cured of neoplasms in childhood].

Various late complications of the chemotherapy or radiotherapy have been discussed with special reference to rare life-threatening side-effects. The long term strategy of patient's care and preliminary principles of prevention of above complications have also been presented. It has been emphasized that life-threatening complications occurring in a small percentage of patients are not indications for limited or ineffective therapy giving no chance of saving of numerous children.

Adult↗
PubMed1992

[Second cessation of therapy in children with acute lymphoblastic leukemia].

In the group of 63 children in whom a relapse of ALL after first suspension of treatment occurred, and in whom a repeated cessation of therapy had place, 46.2% of patients had probability of a prolonged symptomless survival. The children with an isolated extramedullary relapse had a greater chance for a DFS of 7 years, than those with a relapse in the bone marrow (p = 0.05). The patients with a relapse occurring after the first cessation of treatment of ALL should be treated as intensively as newly diagnosed cases, because they have a real possibility for a prolonged survival during remission phase of disease.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1991

[The fate of children after discontinuation of treatment for acute lymphoblastic leukemia].

Among 1879 children with the diagnosis of acute lymphoblastic leukaemia made up to Dec 31 1987 in 863 cases (45.92%) treatment was discontinued. They were followed up till Dec 31 1989. The median follow-up was 3 years and 14 months. In 811 cases the treatment was discontinued during the first complete remission, in 56 cases after a relapse during initial treatment. In the time period when the programmes St. Jude and LSA2L2 were used the per cent of children with treatment withdrawal was 38.22%, but it rose to 53.01% when a more intensive programme BMF had been introduced. The probability of 7-year disease free survival after treatment discontinuation was 69.5% and 76.2% respectively. In 186 cases (21.6%) relapses developed., mostly in the first year after treatment discontinuation, but even after 7 years the risk of relapse was 2.46%. Ninety-six children (11.2%) died, 761 (88.8%) are alive, among them 671 in the first complete remission. Apart from therapy intensity, a statistically significant beneficial effect on disease free survival had discontinuation of treatment during the first complete remission, and sex--the prognosis was better in girls. In three cases secondary neoplasms were found.

Adolescent↗
PubMed1989

[Proposed regimens for chemotherapy and radiotherapy to control preliminary failures of combined therapy in Hodgkin's disease].

Both regimens concern children who underwent--depending on the stage of the disease--three different therapeutical regimens: B-DOPA and/or MVPP combined with radiotherapy. Depending on the results of this treatment, each out of four saving regimens includes two types of chemotherapy: B-DOPA/CAD, MVPP/CAD, MOP-P/ABV/CAD, and MVPP/B-DOPA in case of delayed recurrence. Each cycle of chemotherapy should be introduced with high frequency. Doses of irradiation being additional method and indicated in some patients are given.

Antineoplastic Combined Chemotherapy Protocols↗